Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p

European Journal of Haematology

Volumn 87, Issue 4, 2011, Pages 372-375

  Arumainathan, Arvind ^a   Kalakonda, Nagesh ^a,b   Pettitt, Andrew R ^a,b  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

17p deletion; Alemtuzumab; Chronic lymphocytic leukaemia; Glucocorticoid; Lenalidomide; T cell depletion

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ALLOPURINOL; COTRIMOXAZOLE; DEXAMETHASONE; ITRACONAZOLE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; PREDNIMUSTINE;

ABDOMINAL DISTENSION; ADJUVANT THERAPY; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CELL STIMULATION; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ASSESSMENT; CLOSTRIDIUM DIFFICILE INFECTION; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HYDRONEPHROSIS; INFECTION PREVENTION; LOADING DRUG DOSE; LYMPHADENOPATHY; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MALE; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PANCYTOPENIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; T CELL DEPLETION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VIRUS REACTIVATION;

ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE DEPLETION; T-LYMPHOCYTES; THALIDOMIDE;

EID: 80053257480     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01667.x     Document Type: Article

References (23)

1. Awan FT, Johnson AJ, Lapalombella R, Hu W, Lucas M, Fischer B, Byrd JC. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2010;51:27-38.
2. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukaemia: results of a phase II study. J Clin Oncol 2006;24:5343-9.
3. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291-7.
4. Corral LG, Haslett PAJ, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 1999;163:380-6.
5. LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004;103:1787-90.
6. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-50.
7. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-6.
8. Lapalombella R, Yu B, Triantafillou G, et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukaemia cells. Blood 2008;112:5180-9.
9. Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumour flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26:2519-25.
10. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, Byrd JC, Gribben JG. Chronic lymphocytic leukaemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulatory drug. J Clin Invest 2008;118:2427-33.
11. Lapalombella R, Andritsos L, Liu Q, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 2010;115:2619-29.
12. Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009;27:4578-84.
13. Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-Line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG) (abstract). Blood 2009;114:205a.
14. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-74.
15. Dohner H, Fischer K, Bentz M, et al. p53 Gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580-9.
16. Pettitt AR. Glucocorticoid-based combination therapy for chronic lymphocytic leukemia: new tricks for an old dog. Leuk Lymphoma 2008;49:1843-5.
17. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:3994-4001.
18. Osterborg A, Foa R, Bezares RF, et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009;23:1980-8.
19. Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006;20:1441-5.
20. Ferrajoli A, Keating MJ, Wierda WG, O'Brien S, Padmanabhan S, Czuczman M, Chanan-Khan A. Lenalidomide is active in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) carrying unfavorable chromosomal abnormalities (abstract). Blood 2007;110:754a.
21. Ishioka C, Frebourg T, Yan YX, Vidal M, Friend SH, Schmidt S, Iggo R. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet 1993;5:124-9.
22. Chanan-Khan A, Miller KC, Lawrence D, Padmanabhan S, Miller A, Hernandez-Illazurri F, Czuxzman MS, Wallace PK, Zeldis JB, Lee K. Tumour flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia. Cancer 2011;117:2127-35.
23. Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J, Wiktor-Jedrzejczak W, Niederwieser D, Hallek M, Montserrat E. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007;21:12-7.